3.045 -0.055 (-1.77%) | 07-26 00:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 2.79 | 1-year : | 3.1 |
Resists | First : | 2.39 | Second : | 2.65 |
Pivot price | 2.11 | |||
Supports | First : | 1.96 | Second : | 1.63 |
MAs | MA(5) : | 2.06 | MA(20) : | 2.16 |
MA(100) : | 2.01 | MA(250) : | 2.38 | |
MACD | MACD : | -0.1 | Signal : | 0 |
%K %D | K(14,3) : | 12.1 | D(3) : | 13.4 |
RSI | RSI(14): 47.8 | |||
52-week | High : | 3.37 | Low : | 1.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ERAS ] has closed above bottom band by 31.6%. Bollinger Bands are 43.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 2.6 - 2.61 | 2.61 - 2.62 |
Low: | 1.99 - 2.01 | 2.01 - 2.02 |
Close: | 2.04 - 2.06 | 2.06 - 2.08 |
Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurotology and central nervous system disorders. The company is headquartered in Zug, Zug and currently employs 11 full-time employees. The firm focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The firm operates through subsidiaries in Switzerland, Ireland and the United States.
Tue, 05 Dec 2023
Altamira Therapeutics to Host Investor & Business Update Call on December 11th - Yahoo Finance
Wed, 29 Nov 2023
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - Yahoo Finance
Fri, 17 Nov 2023
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business - Yahoo Finance
Thu, 15 Jun 2023
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome - Yahoo Finance
Mon, 10 Apr 2023
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with ... - Yahoo Finance
Fri, 21 Oct 2022
Altamira finds buyer for Zilentin inner ear unit so Swiss biotech can go all-in on RNA - Fierce Biotech
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 151 (M) |
Shares Float | 85 (M) |
Held by Insiders | 23.3 (%) |
Held by Institutions | 54.7 (%) |
Shares Short | 9,900 (K) |
Shares Short P.Month | 10,220 (K) |
EPS | -1.74 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.25 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -21.1 % |
Return on Equity (ttm) | -65.5 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.94 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -103 (M) |
Levered Free Cash Flow | -88 (M) |
PE Ratio | -1.2 |
PEG Ratio | 0.1 |
Price to Book value | 0.91 |
Price to Sales | 0 |
Price to Cash Flow | -3.03 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |